Investment in the Team Approach to Enhance the Journal's Impact
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Duerinck J, Lescrauwaet L, Dirven I, Delhaye J, Stevens L, Geeraerts X
. Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma. Neuro Oncol. 2024; 26(12):2208-2221.
PMC: 11630548.
DOI: 10.1093/neuonc/noae177.
View
2.
Sahm F, Aldape K, Brastianos P, Brat D, Dahiya S, von Deimling A
. cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol. 2024; 27(2):319-330.
PMC: 11812049.
DOI: 10.1093/neuonc/noae170.
View
3.
Rahman R, Preusser M, Tsien C, Le Rhun E, Sulman E, Wen P
. Point/Counterpoint: The role of reirradiation in recurrent glioblastoma. Neuro Oncol. 2024; 27(1):7-12.
PMC: 11726241.
DOI: 10.1093/neuonc/noae209.
View
4.
Muller K, Forbrig R, Reis J, Wiegand L, Barci E, Kunte S
. Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments. Neuro Oncol. 2024; 27(1):77-88.
PMC: 11726251.
DOI: 10.1093/neuonc/noae208.
View
5.
McCord M, Sears T, Wang W, Chaliparambil R, An S, Sarkaria J
. The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma. Neuro Oncol. 2024; 27(3):644-651.
PMC: 11889708.
DOI: 10.1093/neuonc/noae257.
View